Authors :
Manav Goenka; Aniket De; Arup Ratan Biswas
Volume/Issue :
Volume 5 - 2020, Issue 9 - September
Google Scholar :
http://bitly.ws/9nMw
Scribd :
https://bit.ly/33uhiNN
DOI :
10.38124/IJISRT20SEP592
Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.
Abstract :
Mutations and fusions in kinase enzymes are
often observed in cancer prognosis. The growth and
survival of tumor cells depend on the activation of kinase
enzymes which when activated unrestrained can lead to
the uncontrolled division of malignant lung cells. Thus,
their inhibition is viewed as a promising and effective
anti-cancer therapy. ROS1 and EGFR are two tyrosine
kinases that have been explored as the genes responsible
for Non-Small Cell Lung Cancer (NSCLC). By
interrupting the unchecked division of these genes, the
development of malignant lung cancer cells can be
blocked. The results show 4 of the top-line RNAs for
altering the gene quality as well as the target sequences
relevant to cleavage by that gRNA, 4 for each gene. We
propose a genetic approach of controlling the ROS1 and
EGFR genes guided by CRISPR/Cas-9 to guarantee
fewer symptoms and an increasingly powerful treatment,
by the use of computational tools.
Keywords :
CRISPR; Cas-9; Lung cancer; EGFR; ROS1; Synthego.
Mutations and fusions in kinase enzymes are
often observed in cancer prognosis. The growth and
survival of tumor cells depend on the activation of kinase
enzymes which when activated unrestrained can lead to
the uncontrolled division of malignant lung cells. Thus,
their inhibition is viewed as a promising and effective
anti-cancer therapy. ROS1 and EGFR are two tyrosine
kinases that have been explored as the genes responsible
for Non-Small Cell Lung Cancer (NSCLC). By
interrupting the unchecked division of these genes, the
development of malignant lung cancer cells can be
blocked. The results show 4 of the top-line RNAs for
altering the gene quality as well as the target sequences
relevant to cleavage by that gRNA, 4 for each gene. We
propose a genetic approach of controlling the ROS1 and
EGFR genes guided by CRISPR/Cas-9 to guarantee
fewer symptoms and an increasingly powerful treatment,
by the use of computational tools.
Keywords :
CRISPR; Cas-9; Lung cancer; EGFR; ROS1; Synthego.
